AN2 THERAPEUTICS INC (ANTX) — insider trading
Health Care · NASDAQ
AN2 THERAPEUTICS INC (ANTX) has 30 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 30 (latest 2026-07-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Martin Patricia A. | Director | Grant / award / vesting | 766 | $0.00 | $0 | Form 4 |
| 2026-07-10 | Marks Gilbert Lynn | Director | Grant / award / vesting | 2,789 | $0.00 | $0 | Form 4 |
| 2026-07-10 | Aziz Kabeer | Director | Grant / award / vesting | 2,852 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Eizen Joshua M | Officer (See Remarks) | Open-market sale | 5,945 | $4.17 | $24.8K | Form 4 |
| 2026-05-29 | Williams Sarah Joanne | Officer (Principal Accounting Officer) | Open-market sale | 265 | $4.43 | $1.2K | Form 4 |
| 2026-04-10 | Martin Patricia A. | Director | Grant / award / vesting | 1,192 | $0.00 | $0 | Form 4 |
| 2026-04-10 | Marks Gilbert Lynn | Director | Grant / award / vesting | 3,775 | $0.00 | $0 | Form 4 |
| 2026-04-10 | Aziz Kabeer | Director | Grant / award / vesting | 3,775 | $0.00 | $0 | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Disposition to the issuer (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Grant / award / vesting (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Disposition to the issuer (derivative) | 20,724 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Grant / award / vesting (derivative) | 20,724 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 10,362 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 10,362 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 10,665 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 10,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 41,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 41,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 57,950 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 57,950 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 82,300 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 82,300 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 73,665 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 73,665 | — | — | Form 4 |
Ask the chat about ANTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AN2 THERAPEUTICS INC (ANTX).
Last updated 2026-07-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.